Teva Pharmaceutical Industries Limited (IL:TEVA)
TASE:TEVA
Want to see IL:TEVA full AI Analyst Report?
TEVA Stock Chart & Stats
9672.00
0.44(0.56%)
At close: 4:00 PM EST
9672.00
0.44(0.56%)
Day’s Range― - ―
52-Week Range5,305.00 - 11,350.00
Previous CloseN/A
Volume1.42M
Average Volume (3M)1.92M
Market Cap
₪121.70B
Enterprise Value56.18B
Total Cash (Recent Filing)₪3.78B
Total Debt (Recent Filing)₪17.07B
Price to Earnings (P/E)22.9
Beta0.58
Next Earnings
Aug 05, 2026EPS Estimate
177.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.38
Shares Outstanding1,164,638,700
10 Day Avg. Volume1,312,069
30 Day Avg. Volume1,917,294
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.58
Price to Sales (P/S)1.94
P/FCF Ratio14.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪13,708.00Price Target Upside41.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)7.11
Revenue Forecast (FY)₪49.80B
Bulls Say, Bears Say
Bulls Say
Improving ProfitabilityTeva has shifted from prior loss-making years to sustained positive margins (TTM ~9% net, ~13% EBIT), demonstrating durable operational improvement. Stronger margins indicate better pricing, cost control and portfolio mix, supporting operating resilience and capacity to fund R&D and strategic priorities over coming quarters.
Solid Cash GenerationMeaningful and improving free cash flow (FCF) provides durable financial flexibility: it supports debt reduction, reinvestment, and potential buybacks without relying on external financing. High FCF coverage of earnings signals real cash conversion that sustains operations and strategic investments across a 2–6 month horizon and beyond.
Diversifying, Higher‑value PortfolioA shift toward innovative medicines and scaled biosimilars materially improves revenue mix and reduces reliance on low‑margin commodity generics. Growing high‑value products (AUSTEDO, UZEDY, AJOVY) and an expanding biosimilars pipeline create more stable, higher-margin revenue streams, strengthening long‑term competitive positioning.
Bears Say
Elevated LeverageCapital structure still carries elevated financial risk: leverage above target limits flexibility to invest or absorb shocks. Even with improving cash flow, remaining net debt/EBITDA (~2.4x) constrains capital allocation, raises refinancing sensitivity, and lengthens the timeline to reach investor‑grade profile if earnings weaken.
Generics Revenue PressureMaterial loss of a legacy generic (REVLIMID) and continued pricing/competition in core generics reduce revenue stability and increase reliance on newer products. This mix shift creates structural top‑line headwinds and makes multi‑period revenue forecasting and margin sustainability more sensitive to product launches and tender/contract dynamics.
Acquisition Accounting And Near‑term P&L HitThe Emalex deal is strategically aligned long term but its accounting treatment creates a sizeable near‑term P&L and operating cost burden, pressuring margins and reported earnings in 2026. This temporary earnings drag could slow deleveraging and complicate capital allocation until expected accretion in later years materializes.
Teva News
TEVA FAQ
What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?
Teva Pharmaceutical Industries Limited lowest stock price was 5305.00 and its highest was 11350.00 in the past 12 months.
What is Teva Pharmaceutical Industries Limited’s market cap?
Teva Pharmaceutical Industries Limited’s market cap is ₪121.70B.
When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?
Teva Pharmaceutical Industries Limited’s upcoming earnings report date is Aug 05, 2026 which is in 88 days.
How were Teva Pharmaceutical Industries Limited’s earnings last quarter?
Teva Pharmaceutical Industries Limited released its earnings results on Apr 29, 2026. The company reported 157.6 earnings per share for the quarter, beating the consensus estimate of 142.9 by 14.7.
Is Teva Pharmaceutical Industries Limited overvalued?
According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Undervalued.
Does Teva Pharmaceutical Industries Limited pay dividends?
Teva Pharmaceutical Industries Limited pays a Quarterly dividend of 8.5 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical Industries Limited dividends here
What is Teva Pharmaceutical Industries Limited’s EPS estimate?
Teva Pharmaceutical Industries Limited’s EPS estimate is 177.1.
How many shares outstanding does Teva Pharmaceutical Industries Limited have?
Teva Pharmaceutical Industries Limited has 1,164,638,700 shares outstanding.
What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?
Teva Pharmaceutical Industries Limited reported an EPS of 157.6 in its last earnings report, beating expectations of 142.9. Following the earnings report the stock price went up 9.759%.
Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?
Currently, no hedge funds are holding shares in IL:TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
TEVA Stock 12 Month Forecast
Average Price Target
13,708.00
▲(41.73% Upside)